Novo Nordisk A/S (NYSE:NVO – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They presently have a $160.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 50.26% from the stock’s current price.
NVO has been the subject of a number of other reports. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $144.50.
Check Out Our Latest Report on NVO
Novo Nordisk A/S Trading Down 1.1 %
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The company had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Equities analysts expect that Novo Nordisk A/S will post 3.01 earnings per share for the current year.
Institutional Trading of Novo Nordisk A/S
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisor OS LLC grew its position in Novo Nordisk A/S by 0.6% during the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after buying an additional 82 shares during the period. Cascade Financial Partners LLC grew its position in shares of Novo Nordisk A/S by 2.3% during the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after acquiring an additional 84 shares during the period. Novare Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares in the last quarter. AA Financial Advisors LLC raised its holdings in Novo Nordisk A/S by 3.2% in the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after purchasing an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC boosted its position in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after purchasing an additional 86 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Why Invest in High-Yield Dividend Stocks?
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- What Investors Need to Know to Beat the Market
- L3Harris: Positioned for Gains With Trump’s Defense Policies
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.